UNSPSC 51111829: Abarelix

This classification denotes a gonadotropin releasing hormone inhibitor with the molecular formula C72H95ClN14O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W486SJ5824, chemically known as d-alaninamide, n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-n-methyl-l-tyrosyl-d-asparaginyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl- 10 but generally known as abarelix, which bears US NIH Compound Identifier 16131215.

UNSPSC 51111829 Abarelix is a Commodity code covering the procurement of specific active pharmaceutical ingredients and finished drugs, which state and local governments acquire primarily through cooperative purchasing agreements that bundle multiple drugs and OTC products into multi-source contracts. The work being solicited under this code involves manufacturers and distributors supplying pharmaceutical products with defined National Drug Codes (NDCs), specific dosages, and packaging configurations to state and local healthcare facilities, correctional institutions, and other public agencies through authorized wholesale channels. Issuing bodies include state departments of administration and health, counties, cities, and special-purpose districts participating in multistate cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves as a representative vehicle consolidating demand across multiple participating jurisdictions and states.

The most recent activity supporting this code centers in Minnesota and the Pacific Northwest, with MMCAP's January 2026 Request for Proposal for generic multi-source pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026) representing the primary current opportunity. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing evaluated on competitiveness (75 percent weight), fixed pricing and administrative compliance (20 percent combined), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). All products must achieve market availability by May 15, 2026, with resulting contracts effective July 1, 2026. Vendors must certify cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with at least two of the three authorized wholesalers, carry insurance coverage including $5 million commercial general liability and $2 million network security liability, and accept performance penalties ranging from $200 to $1,500 per violation. The contract term extends two years for new responders with optional extensions, while incumbent amendments align through June 30, 2028.